The stock of niche financial software company Vertex (NASDAQ: VERX) didn't get a very good start to the trading week at all.
Vertex Pharmaceuticals (VRTX) is rated as a "Strong Buy" due to robust revenue growth and multiple expansion opportunities ...
One key figure, however, indicates otherwise as sales for Journavx were at $20 million for the period, coming up $3 million ...
The potential approval of Vertex’s IgAN therapy povetacicept in 2026 comes amid launch headwinds for the company’s non-opioid ...
Vertex (NASDAQ: VERX) has been analyzed by 7 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. Summarizing their recent assessments, the table below ...
While the launches of Journavx and Casgevy have started to build steam, “investors may not be inclined to look past the clear revenue misses,” wrote a Raymond James analyst.
Vertex Pharmaceuticals (VRTX) ended the recent trading session at $407.90, demonstrating a -1.05% change from the preceding day's closing price. The stock's change was less than the S&P 500's daily ...
TipRanks on MSN
Vertex price target lowered to $25 from $32 at Baird
Baird lowered the firm’s price target on Vertex (VERX) to $25 from $32 and keeps a Neutral rating on the shares. The firm updated its model ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback